Enovis™ Companion Animal Health Launches CT-RevitL™, the Next-Generation Laser Therapy System for Veterinary Care
Enovis (NYSE: ENOV) launched CT-RevitL in the United States on July 13, 2026, as a next-generation veterinary photobiomodulation (PBM) laser therapy system from its Companion Animal Health business.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Enovis (NYSE: ENOV) launched CT-RevitL in the United States on July 13, 2026, as a next-generation veterinary photobiomodulation (PBM) laser therapy system from its Companion Animal Health business. According to Enovis, CT-RevitL is built on more than 150 published PBM studies.
The system is designed to deliver deeper, faster and more consistent therapeutic outcomes for animals, aided by Companion’s new COMPASS intelligent treatment guidance technology, which calibrates dosing and reduces treatment variability. Enovis positions CT-RevitL to support drug-sparing pain management, practice efficiency, recurring non-drug care demand and differentiation for veterinary practices across a wide range of conditions.
Details
News Market Reaction – ENOV
On Jul 13, the day this news came out, ENOV closed 1.94% above the previous close. Our momentum scanner recorded 3 alerts for this stock that day.
Data tracked by StockTitan Argus for the Jul 13 session.
Key Figures
- Published PBM studies
- 150+ studies
- Evidence base supporting photobiomodulation therapy cited for CT-RevitL
- PBM experience duration
- more than 15 years
- Companion Animal Health experience advancing PBM laser therapy
- U.S. availability date
- July 13, 2026
- CT-RevitL availability to U.S. veterinary practices
Historical Context
-
Launch of Spinamic Hybrid Scoliosis Brace for adolescent idiopathic scoliosis care.
-
Q1 2026 results with sales growth and reaffirmed full-year revenue and EBITDA guidance.
-
Announcement of Knoa Pharma operations under a public health–focused structure.
-
Scheduling of first quarter 2026 earnings conference call and webcast details.
-
Q4 and full-year 2025 results with growth and 2026 guidance for revenue and EBITDA.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
photobiomodulation medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- CT-RevitL™ launches in the United States, built on a foundation of 150+ published studies on photobiomodulation (PBM) therapy
- Designed to deliver deeper, faster and more consistent therapeutic outcomes for animals
DALLAS, TX, July 13, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology company, today announced the U.S. launch of CT-RevitL™, the next-generation veterinary PBM laser therapy system from its Companion Animal Health business. CT-RevitL delivers enhanced clinical performance, greater mobility and a more intuitive treatment experience for veterinary teams and their patients.
Laser therapy is one of the fastest-growing modalities in veterinary medicine, used to manage pain, accelerate tissue healing, reduce inflammation and support post-operative recovery across a wide range of musculoskeletal and soft-tissue conditions.¹ As pet owners increasingly seek drug-sparing alternatives and practices look for tools that improve both clinical outcomes and practice efficiency, demand for advanced laser therapy continues to grow.²
Companion Animal Health, an Enovis business and the U.S. market leader in veterinary therapeutic laser technology, has spent more than 15 years advancing the science and clinical application of PBM laser therapy. CT-RevitL uses Companion’s new COMPASS technology, an intelligent treatment guidance system that delivers precise, calibrated dosing to help reduce treatment variability and support consistent application across users. By making high-powered laser therapy simpler to deliver and easier to integrate into everyday practice workflows, COMPASS helps veterinary teams provide treatment with greater confidence and efficiency.³
"CT-RevitL represents the next chapter in our commitment to deliver practical, innovative, evidence-based veterinary care," said Terry Ross, Group President of Enovis’ Prevention & Recovery business segment, which includes Companion Animal Health. "We have been the trusted partner of veterinary teams across the U.S. for nearly two decades, and CT-RevitL extends that leadership by giving practitioners a more intuitive and consistent way to deliver laser therapy. It is a meaningful step forward for the pets we care for, the practices that rely on us, and the broader advancement of laser therapy as a standard of care in veterinary medicine."
Beyond its clinical applications, CT-RevitL is designed to support practice growth by expanding treatment offerings, encouraging repeatable protocols and helping practices generate recurring demand for non-drug care. By supporting routine use across a broad range of conditions, the system can help practices improve return on investment, strengthen client satisfaction and differentiate themselves as providers of advanced veterinary care.
CT-RevitL is available to veterinary practices across the United States beginning July 13, 2026, with international availability anticipated in subsequent phases. The launch is supported by a comprehensive clinical education program and ongoing partnership from Companion’s veterinary specialists. For more information, visit www.companionanimalhealth.com.
About Enovis
Enovis™ (NYSE: ENOV) is a global medical technology innovator dedicated to improving lives by developing clinically differentiated solutions that enhance patient outcomes and restore motion for life. We partner with the brightest minds in health to advance care that is smarter, personalized, and more effective, while improving operational efficiency for surgeons and clinicians around the world. Enovis solutions impact the well-being of millions of patients wherever they are on their pathway to health. Discover more about Enovis at www.enovis.com.
About Companion Animal Health
Companion Animal Health, a division of Enovis, is a global leader in veterinary medical technology and education. We believe in enhancing animal well-being by providing advanced, non-invasive treatments—such as laser therapy and targeted regenerative solutions—that promote faster healing and pain management. Headquartered in Newark, Delaware, we support veterinary professionals worldwide with innovative equipment and clinical support. For more information, visit www.companionanimalhealth.com.
Trademark Notice
Enovis, CT-RevitL, and Companion Animal Health are trademarks or registered trademarks of Enovis™ Corporation or its affiliates.
Media Contact
Cristina Pasquino
Enovis Corporation
Cristina.Pasquino@enovis.com
References
¹ Riegel RJ, Godbold JC. Laser Therapy in Veterinary Medicine: Photobiomodulation. Wiley-Blackwell; 2017.
² Pryor B, Millis DL. Therapeutic laser in veterinary medicine. Vet Clin North Am Small Anim Pract. 2015;45(1):45-56. doi:10.1016/j.cvsm.2014.09.003.
³ Companion Animal Health. Publications: scientific studies on photobiomodulation and laser therapy. Available at: publications.companionanimalhealth.com.
Attachment
Cristina Pasquino Enovis Corporation Cristina.Pasquino@enovis.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.